Anti-pentraxin antibodies in autoimmune systemic diseases: Focus on anti-pentraxin-3 autoantibodies

References

• Jeannin P, Jaillon S, Delneste Y. Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 2008;20(5):530– 537.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140(6):805–820.
   PubMed Web of Science ®Google Scholar
• Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002;2(12):965– 975.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev 2011;243(1):61–73.
   PubMed Web of Science ®Google Scholar
• Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The long pentraxin 3 and its role in autoimmunity. Semin Arthr Rheum 2009;39(1):38–54.
   PubMed Web of Science ®Google Scholar
• Augusto JF, Onno C, Blanchard S, Dubuquoi S, MantovaniA, Chevailler A, et al. Detection of anti-PTX3 autoantibodies in systemic lupus erythematosus. Rheumatology 2009;48(4):442–444.
   PubMed Web of Science ®Google Scholar
• Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A, et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010;69(9):1704–1710.
   PubMed Web of Science ®Google Scholar
• Bell SA, Du Clos TW, Khursigara G, Picazo JJ, Rubin RL. Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome. J Autoimmun 1995;8(2):293–303.
   PubMed Web of Science ®Google Scholar
• Bell SA, Faust H, Schmid A, Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 1998;113(3):327–332.
   PubMed Web of Science ®Google Scholar
• Figueredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 2006;33(10):1980–1986.
   PubMed Web of Science ®Google Scholar
• Rosenau BJ, Schur PH. Antibodies to C reactive protein. Ann Rheum Dis 2006;65(5):674–676.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Szyper-Kravitz M, Witte T, Doria A, Tsutsumi A, Tatsuya A, et al. Autoantibodies against protective molecules–C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:227–239.
   PubMed Web of Science ®Google Scholar
• Simon A, Subra JF, Guilpain P, Jeannin P, Pignon P, Blanchard S, et al. Detection of anti-pentraxin-3 autoantibodies in ANCA-associated vasculitis. PloS One 2016;11(1):e0147091.
   PubMed Web of Science ®Google Scholar
• Sjowall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthr Res Ther 2004;6(2):R87–R94.
   PubMed Web of Science ®Google Scholar
• Sjowall C, Bengtsson AA, Sturfelt G, Skogh T. Anti-CRP autoantibody levels correlate with disease activity in systemic lupus erythematosus. Semin Arthr Rheum 2005;35(1):65; author reply 6.
   PubMed Web of Science ®Google Scholar
• Sjowall C, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002;19(3):155–160.
   PubMed Web of Science ®Google Scholar
• Sjowall C, Zickert A, Skogh T, Wettero J, Gunnarsson I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthr Res Ther 2009;11(6):R188.
   PubMed Web of Science ®Google Scholar
• Tan Y, Yu F, Yang H, Chen M, Fang Q, Zhao MH. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol 2008;69(12):840–844.
   PubMed Web of Science ®Google Scholar
• Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol 1995;7(1):54–64.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vasc Pharmacol 2006;45(5):326–330.
   PubMed Web of Science ®Google Scholar
• Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res 2011;343(1):237–249.
   PubMed Web of Science ®Google Scholar
• Du Clos TW. Pentraxins: structure, function, and role in inflammation. ISRN Inflammation 2013;2013:379040.
   PubMedGoogle Scholar
• Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, et al. Structure of pentameric human serum amyloid P component. Nature 1994;367(6461):338–345.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805–1812.
   PubMed Web of Science ®Google Scholar
• Szalai AJ, van Ginkel FW, Wang Y, McGhee JR, Volanakis JE. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol 2000;165(2):1030–1035.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Ann Rev Immunol 2005;23:337–366.
   PubMed Web of Science ®Google Scholar
• Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267(31):22190–22197.
   PubMed Web of Science ®Google Scholar
• Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, Scarchilli L, et al. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem 2008;283(15):10147–10161.
   PubMed Web of Science ®Google Scholar
• Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110(16):2349–2354.
   PubMed Web of Science ®Google Scholar
• Sjoberg B, Qureshi AR, Anderstam B, Alvestrand A, Barany P. Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation. Blood Purificat 2012;34(3, 4):290–297.
   PubMed Web of Science ®Google Scholar
• Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29(7):1404–1407.
   PubMed Web of Science ®Google Scholar
• Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, et al. Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 1997;272(13):8172– 8178.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007;204(4):793–804.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009;15(6):623–625.
   PubMed Web of Science ®Google Scholar
• Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192(9):1353–1364.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A. Pattern recognition by pentraxins. Adv Exp Med Biol 2009;653:98–116.
   PubMed Web of Science ®Google Scholar
• Weiser JN, Pan N, McGowan KL, Musher D, Martin A, Richards J. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998;187(4):631–640.
   PubMed Web of Science ®Google Scholar
• Mold C, Rodgers CP, Kaplan RL, Gewurz H. Binding of human C-reactive protein to bacteria. Infect Immun 1982;38(1):392–395.
   PubMed Web of Science ®Google Scholar
• de Haas CJ, van Leeuwen EM, van Bommel T, Verhoef J, van Kessel KP, van Strijp JA. Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation. Infect Immun 2000;68(4):1753–1759.
   PubMed Web of Science ®Google Scholar
• Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Nat Acad Sci USA 2000;97(26):14584–14589.
   PubMed Web of Science ®Google Scholar
• Szalai AJ, VanCott JL, McGhee JR, Volanakis JE, Benjamin Jr WH. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun 2000;68(10):5652–5656.
   PubMed Web of Science ®Google Scholar
• Szalai AJ, Briles DE, Volanakis JE. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 1995;155(5):2557–2563.
   PubMed Web of Science ®Google Scholar
• Dias AA, Goodman AR, Dos Santos JL, Gomes RN, Altmeyer A, Bozza PT, et al. TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis. J Leuk Biol 2001;69(6):928–936.
   PubMed Web of Science ®Google Scholar
• Han B, Haitsma JJ, Zhang Y, Bai X, Rubacha M, Keshavjee S, et al. Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury. Intens Care Med 2011;37(2):334–342.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003;24(3):148–154.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Ferguson TA. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity 2011;35(4):456–466.
   PubMed Web of Science ®Google Scholar
• Szondy Z, Garabuczi E, Joos G, Tsay GJ, Sarang Z. Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications. Front Immunol 2014;5:354.
   PubMed Web of Science ®Google Scholar
• Mihlan M, Stippa S, Jozsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 2009;16(12):1630–1640.
   PubMed Web of Science ®Google Scholar
• van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini P, Mantovani A, et al. The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthr Rheum 2004;50(8):2667–2674.
   PubMed Web of Science ®Google Scholar
• Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA, et al. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leuk Biol 2006;80(1):87–95.
   PubMed Web of Science ®Google Scholar
• Rodriguez W, Mold C, Marnell LL, Hutt J, Silverman GJ, Tran D, et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthr Rheum 2006;54(1):325–335.
   PubMed Web of Science ®Google Scholar
• Szalai AJ. C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin Dev Immunol 2004;11(3, 4):221–216.
   PubMedGoogle Scholar
• Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, Kearney JF, et al. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene. Arthr Rheum 2003;48(6):1602–1611.
   PubMed Web of Science ®Google Scholar
• Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5(6):694–697.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Hutchinson WL, Herbert J, Bybee A, Mitchell DA, Hasserjian RP, et al. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? Immunology 2004;112(2):255– 264.
   PubMed Web of Science ®Google Scholar
• Lech M, Rommele C, Kulkarni OP, Susanti HE, Migliorini A, Garlanda C, et al. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PloS One 2011;6(5):e20118.
   PubMed Web of Science ®Google Scholar
• Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 2011;20(6):588–597.
   PubMed Web of Science ®Google Scholar
• Linares LF, Gomez-Reino JJ, Carreira PE, Morillas L, Ibero I. C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE). Clini Rheumatol 1986;5(1):66–69.
   PubMed Web of Science ®Google Scholar
• Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, Voll RE, et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010;15(9):1098–1113.
   PubMed Web of Science ®Google Scholar
• Robey FA, Jones KD, Steinberg AD. C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med 1985;161(6):1344–1356.
   PubMed Web of Science ®Google Scholar
• Eisenhardt SU, Thiele JR, Bannasch H, Stark GB, Peter K. C-reactive protein: how conformational changes influence inflammatory properties. Cell Cycle 2009;8(23):3885–3892.
   PubMed Web of Science ®Google Scholar
• Potempa LA, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H. Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 1988;12(4):391–405.
   PubMed Web of Science ®Google Scholar
• Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000;9(6):445–450.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Blank M, Langevitz P, Slutsky L, Pras M, Levy Y, et al. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis 2005;64(12):1698–1702.
   PubMed Web of Science ®Google Scholar
• Bassi N, Del Prete D, Ghirardello A, Gatto M, Ceol M, Zen M, et al. PTX3, anti-PTX3, and anti-C1q autoantibodies in lupus glomerulonephritis. Clin Rev Allergy Immunol 2015;49(2):217–226.
   PubMed Web of Science ®Google Scholar
• Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British isles lupus assessment group (BILAG 2004), European consensus lupus activity measurements (ECLAM), systemic lupus activity measure, revised (SLAM-R), systemic lupus activity questionnaire for population studies (SLAQ), systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K), and systemic lupus international collaborating clinics/American college of rheumatology damage index (SDI). Arthr Care & Res 2011; 63(Suppl 11):S37–S46.
   PubMed Web of Science ®Google Scholar
• Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19(5):685–708.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Ann Rev Pathol 2013;8:139–160.
   PubMed Web of Science ®Google Scholar
• Beauvillain C, Delneste Y, Renier G, Jeannin P, Subra JF, Chevailler A. Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them? Clin Rev Allergy Immunol 2008;35(1, 2):47–58.
   PubMed Web of Science ®Google Scholar
• Sayegh J, Poli C, Chevailler A, Subra JF, Beloncle F, Deguigne PA, et al. Emergency testing for antineutrophil cytoplasmic antibodies combined with a dialog-based policy between clinician and biologist: effectiveness for the diagnosis of ANCA-associated vasculitis. Intern Emerg Med 2015;10(3):315–319.
   Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangeitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthri Rheum 2013;65(1):270–281.
   PubMed Web of Science ®Google Scholar
• Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013;123(4):1773– 1783.
   PubMed Web of Science ®Google Scholar
• Talor MV, Stone JH, Stebbing J, Barin J, Rose NR, Burek CL. Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 2007;150(1):42–48.
   PubMed Web of Science ®Google Scholar
• Knight JS, Kaplan MJ. Lupus neutrophils: “NET” gain in understanding lupus pathogenesis. Curr Opin Rheumatol 2012;24(5):441–450.
   PubMed Web of Science ®Google Scholar
• Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Front Immunol 2012;3:380.
   PubMed Web of Science ®Google Scholar
• Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13(5):543–451.
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294(5546):1540–1543.
   PubMed Web of Science ®Google Scholar
• Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010;184(6):3284–3297.
   PubMed Web of Science ®Google Scholar
• Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187(1):538–552.
   PubMed Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011;3(73):73ra19.
   PubMed Web of Science ®Google Scholar
• Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011;3(73):73ra20.
   PubMed Web of Science ®Google Scholar
• Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 2012;120(15):3007–3018.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Jeannin P, Hamon Y, Fremaux I, Doni A, Bottazzi B, et al. Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ 2009;16(3):465–474.
   PubMed Web of Science ®Google Scholar
• Daigo K, Hamakubo T. Host-protective effect of circulating pentraxin 3 (PTX3) and complex formation with neutrophil extracellular traps. Front Immunol 2012;3:378.
   PubMed Web of Science ®Google Scholar
• Daigo K, Yamaguchi N, Kawamura T, Matsubara K, Jiang S, Ohashi R, et al. The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps. Mol Cell Prot 2012;11(6):M111 015073.
   PubMed Web of Science ®Google Scholar
• Tan Y, Yu F, Qu Z, Su T, Xing GQ, Wu LH, et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Amer Soc Neph 2011;6(1):93–100.
   PubMed Web of Science ®Google Scholar